Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05128383
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1324
- Registration Number
- NCT05097287
- Locations
- 🇺🇸
Chandler Clinical Research Trials- Site Number : 8400147, Chandler, Arizona, United States
🇺🇸Pulmonary Associates - Deer Valley Office- Site Number : 8400155, Phoenix, Arizona, United States
🇺🇸Alpha Clinical Research Group - Dunwoody- Site Number : 8400116, Dunwoody, Georgia, United States
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 40
- Registration Number
- NCT05042258
- Locations
- 🇺🇸
Lurie Children's Hospital/Northwestern University, Chicago, Illinois, United States
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 15
- Registration Number
- NCT05036733
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Dupilumab_Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Thomas Marron
- Target Recruit Count
- 21
- Registration Number
- NCT05013450
- Locations
- 🇺🇸
Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, United States
🇺🇸The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York, New York, United States
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 320
- Registration Number
- NCT04998604
- Locations
- 🇺🇸
Cedars Sinai Medical Center Site Number : 8400026, Los Angeles, California, United States
🇺🇸Northwell Health Site Number : 8400044, Great Neck, New York, United States
🇺🇸Cleveland Clinic Foundation Site Number : 8400029, Cleveland, Ohio, United States
Dupilumab in the Treatment of Keloids
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 44
- Registration Number
- NCT04988022
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 199
- Registration Number
- NCT04791319
- Locations
- 🇺🇸
Park Avenue Dermatology, Orange Park, Florida, United States
🇺🇸Clinical Partners, Johnston, Rhode Island, United States
🇨🇦Centre De Recherche Dermatologique Du Quebec Metropolitan, Quebec, Canada
Compassionate Use of Dupilumab
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT04776694
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sally E. Wenzel MD
- Target Recruit Count
- 30
- Registration Number
- NCT04743791
- Locations
- 🇺🇸
The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.